今日观察！A Wave of "Kete Valuation" Sweeps Through the Market: 50 Stocks Poised for Strong Growth

A Wave of "Kete Valuation" Sweeps Through the Market: 50 Stocks Poised for Strong Growth

Shanghai, China - June 17, 2024 - A recent surge in investor sentiment towards growth stocks, particularly in the healthcare and technology sectors, has been dubbed the "Kete Valuation" phenomenon, named after the Chinese pharmaceutical company C-Bridge (6160.HK). This trend is reminiscent of the "CATL Valuation" rally that occurred in 2021, driven by the strong performance of Contemporary Amperex Technology Co., Ltd. (300015.SZ).

The "Kete Valuation" is characterized by a sharp increase in the share prices of companies with promising growth prospects, often defying broader market trends. This is evident in the recent performance of 50 stocks identified by analysts as having significant growth potential. These stocks, spanning various industries including healthcare, technology, and consumer goods, have exhibited remarkable resilience amidst recent market volatility.

Factors Driving the "Kete Valuation"

Several factors are contributing to the "Kete Valuation" trend. Firstly, investors are increasingly seeking out companies that can deliver sustainable growth, particularly in the face of global economic uncertainties. Secondly, the easing of monetary policy in major economies is providing a supportive backdrop for riskier assets like growth stocks. Additionally, advancements in technology and innovation are creating new opportunities for companies in various sectors, fueling investor optimism.

Key Beneficiaries of the "Kete Valuation"

Among the 50 stocks identified as potential beneficiaries of the "Kete Valuation," C-Bridge (6160.HK) stands out as a frontrunner. The company's innovative cancer therapies and strong pipeline of new drugs have attracted significant investor interest. Other notable stocks include:

• Ascletis Pharma (1672.HK): A clinical-stage biopharmaceutical company developing novel therapies for cancer and viral diseases.

• Aier Eye Hospital Group (300015.SZ): A leading provider of comprehensive eye care services in China.

• Xiaomi Corporation (1810.HK): A global technology company known for its smartphones, smart home devices, and internet services.

Investment Implications

The "Kete Valuation" presents an opportunity for investors to capitalize on the growth potential of select companies. However, careful due diligence is crucial, as not all growth stocks are created equal. Investors should thoroughly evaluate a company's financial health, competitive landscape, and long-term growth prospects before making investment decisions.

The "Kete Valuation" highlights the evolving dynamics of the Chinese stock market, where investors are increasingly discerning and seeking out companies with genuine growth potential. This trend is likely to continue as China's economy transitions towards a more innovation-driven and knowledge-based model.

ST爱康被立案调查 股民维权或迎曙光

ST爱康（002610） 陷入财务困境，连续三年净利润为负，股票面临退市风险。近日，证监会对公司及实际控制人邹承慧涉嫌信息披露违法违规立案调查，为股民维权注入了新的希望。

维权时间范围：

根据《最高人民法院关于审理证券市场因虚假陈述引发的民事赔偿案件的若干规定》，ST爱康股民可在 2024年2月6日至2024年4月30日 收盘前买入并持有股票者，可以依法向公司维权索赔。

维权条件：

1. 在法定期限内买入并持有ST爱康股票；
2. 能提供完整的股票交易凭证；
3. 符合相关法律法规规定的其他条件。

维权流程：

1. 股民可以收集相关证据材料，如证券账户对账单、交易记录、身份证明等；
2. 选择一家维权律师事务所，委托律师代理维权；
3. 律师会指引股民完成后续的维权程序，包括参加听证、诉讼等。

维权金额计算：

ST爱康股民的损失金额一般按照以下公式计算：

损失金额 = (买入价 - 卖出价) * 股票数量 + 应收股息

其中，买入价以投资人实际买入股票的价格为准，卖出价以投资人实际卖出股票的价格为准，应收股息以投资人持有股票期间所应收取的股息为准。

需要注意的是， 以上内容仅供参考，不构成任何法律意见。股民应根据自身情况，咨询专业律师，寻求法律帮助。

以下为此次维权事件的最新进展：

• 2024年6月12日， ST爱康发布公告称，公司及实际控制人邹承慧收到证监会下发的《立案告知书》。
• 2024年6月13日， 多家维权律师事务所发布维权公告，表示将代理ST爱康股民依法维权。

维权分析：

ST爱康被立案调查，为股民维权提供了有利的法律依据。根据以往类似案件的判决结果，股民胜诉的可能性较大。但维权过程可能较长，需要投资者耐心等待。

投资者应理性维权， 依法维护自身合法权益。同时，也要注意甄别虚假信息，选择正规的维权渠道。